Why Is Johnson & Johnson (JNJ) Down 6.7% Since Last Earnings Report?
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Benefits Pro1h
Johnson & Johnson sues federal government over legality of plan to offer 340B rebates
Johnson & Johnson on Tuesday sued the Biden administration in a controversy over how it distributes rebates under the federal ...
JNJ's Phase 2 Study Of Nipocalimab Shows Improvement In Disease Activity In Sjögren's Disease
(RTTNews) - Johnson & Johnson (JNJ), Thursday announced results from additional analyses of the Phase 2 DAHLIAS study, evaluating the effects of Nipocalimab in participants with primary Sjogren's ...
Taiwan News3h
Nipocalimab demonstrates significant clinical improvement in disease activity and IgG reduction in Phase 2 Sjögren’s disease study
Nipocalimab was well-tolerated over the six-month study period, with no major safety signals observed. The most common adverse events (AEs) were infections and infestations: 60.4% (n=32) in the ...
Why Are These 3 Vanguard ETFs Underperforming the S&P 500 Since Election Day?
Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.
MassDevice18h
Johnson & Johnson MedTech inks distro deal to expand soft tissue solutions
Johnson & Johnson MedTech announced today that it entered into an exclusive commercial distribution agreement with Responsive Arthroscopy. The company agreed to a deal in the U.S. with Responsive ...